Ministry of Health, Community Development, Gender, Elderly and Children, Dar es Salaam, Tanzania.
Institute of Public Health, Kilimanjaro Christian Medical University College, Moshi, Tanzania.
PLoS One. 2021 Jul 13;16(7):e0254082. doi: 10.1371/journal.pone.0254082. eCollection 2021.
Information on how well Isoniazid Preventive Therapy (IPT) works on reducing TB incidence among people living with HIV (PLHIV) in routine settings using robust statistical methods to establish causality in observational studies is scarce.
To evaluate the effectiveness of IPT in routine clinical settings by comparing TB incidence between IPT and non-IPT groups.
We used data from PLHIV enrolled in 315 HIV care and treatment clinic from January 2012 to December 2016. We used Inverse Probability of Treatment Weighting to adjust for the probability of receiving IPT; balancing the baseline covariates between IPT and non-IPT groups. The effectiveness of IPT on TB incidence was estimated using Cox regression using the weighted sample.
Of 171,743 PLHIV enrolled in the clinics over the five years, 10,326 (6.01%) were excluded leaving 161,417 available for the analysis. Of the 24,800 who received IPT, 1.00% developed TB disease whereas of the 136,617 who never received IPT 6,085 (4.98%) developed TB disease. In 278,545.90 person-years of follow up, a total 7,052 new TB cases were diagnosed. Using the weighted sample, the overall TB incidence was 11.57 (95% CI: 11.09-12.07) per 1,000 person-years. The TB incidence among PLHIV who received IPT was 10.49 (95% CI: 9.11-12.15) per 1,000 person-years and 12.00 (95% CI: 11.69-12.33) per 1,000 person-years in those who never received IPT. After adjusting for other covariates there was 52% lower risk of developing TB disease among those who received IPT compared to those who never received IPT: aHR = 0.48 (95% CI: 0.40-0.58, P<0.001).
IPT reduced TB incidence by 52% in PLHIV attending routine CTC in Tanzania. IPTW adjusted the groups for imbalances in the covariates associated with receiving IPT to achieve comparable groups of IPT and non-IPT. This study has added evidence on the effectiveness of IPT in routine clinical settings and on the use of IPTW to determine impact of interventions in observational studies.
关于异烟肼预防治疗(IPT)在常规环境下降低 HIV 感染者(PLHIV)结核病发病率的效果,使用强大的统计方法来确定观察性研究中的因果关系的信息很少。
通过比较 IPT 组和非 IPT 组的结核病发病率,评估 IPT 在常规临床环境中的效果。
我们使用了 2012 年 1 月至 2016 年 12 月期间参加 315 个 HIV 护理和治疗诊所的 PLHIV 的数据。我们使用逆概率治疗权重(Inverse Probability of Treatment Weighting)来调整接受 IPT 的概率;平衡 IPT 组和非 IPT 组之间的基线协变量。使用加权样本的 Cox 回归估计 IPT 对结核病发病率的影响。
在五年期间,共有 171743 名 PLHIV 参加了诊所,其中 10326 名(6.01%)被排除在外,剩下 161417 名可供分析。在接受 IPT 的 24800 人中,有 1.00%发生结核病,而在从未接受 IPT 的 136617 人中,有 6085 人(4.98%)发生结核病。在 278545.90 人年的随访中,共诊断出 7052 例新结核病病例。使用加权样本,总体结核病发病率为每 1000 人年 11.57(95%CI:11.09-12.07)。接受 IPT 的 PLHIV 的结核病发病率为每 1000 人年 10.49(95%CI:9.11-12.15),而从未接受 IPT 的 PLHIV 的结核病发病率为每 1000 人年 12.00(95%CI:11.69-12.33)。在调整其他协变量后,接受 IPT 的患者发生结核病的风险比未接受 IPT 的患者低 52%:调整后 HR = 0.48(95%CI:0.40-0.58,P<0.001)。
在坦桑尼亚接受常规 CTC 的 PLHIV 中,IPT 使结核病发病率降低了 52%。IPTW 调整了与接受 IPT 相关的协变量的不平衡,以实现 IPT 组和非 IPT 组的可比性。这项研究为 IPT 在常规临床环境中的效果以及 IPTW 在观察性研究中确定干预效果提供了额外的证据。